|1.59||-0.0527||-3.21%||Vol 128.30K||1Y Perf -23.56%|
|Jul 27th, 2021 14:44 DELAYED|
|0.02 1.22%||- -|
|Target Price||5.00||Analyst Rating||Strong Buy 1.00|
|Potential %||220.51||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Market Cap||75.55M||Earnings Rating||Neutral|
|Price Range Ratio 52W %||6.00||Earnings Date||7th Sep 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||7th Sep 2021|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||103.14K|
|Avg. Monthly Volume||116.73K|
|Avg. Quarterly Volume||421.93K|
Akari Therapeutics Plc (NASDAQ: AKTX) stock closed at 1.64 per share at the end of the most recent trading day (a 1.23% change compared to the prior day closing price) with a volume of 88.73K shares and market capitalization of 75.55M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. Akari Therapeutics Plc CEO is Clive Richardson.
The one-year performance of Akari Therapeutics Plc stock is -23.56%, while year-to-date (YTD) performance is -11.35%. AKTX stock has a five-year performance of -81.57%. Its 52-week range is between 1.42 and 4.21, which gives AKTX stock a 52-week price range ratio of 6.00%
Akari Therapeutics Plc currently has a PE ratio of -1.50, a price-to-book (PB) ratio of 16.52, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -207.92%, a ROC of -667.23% and a ROE of -653.52%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Akari Therapeutics Plc, there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Akari Therapeutics Plc’s next earnings report date is 07th Sep 2021.
The consensus rating of Wall Street analysts for Akari Therapeutics Plc is Strong Buy (1), with a target price of $5, which is +220.51% compared to the current price. The earnings rating for Akari Therapeutics Plc stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Akari Therapeutics Plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Akari Therapeutics Plc has a Sell technical analysis rating based on Technical Indicators (ADX : 17.50, ATR14 : 0.08, CCI20 : -58.52, Chaikin Money Flow : -0.16, MACD : -0.04, Money Flow Index : 51.55, ROC : 0.61, RSI : 43.32, STOCH (14,3) : 26.67, STOCH RSI : 0.64, UO : 41.39, Williams %R : -73.33), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Akari Therapeutics Plc in the last 12-months were:
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.